Navigation Links
In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment
Date:12/27/2007

ould talk to their doctors to be sure they are receiving the most effective therapy."

Reported in the same journal is a subanalysis of the WIN-R data that evaluates the efficacy of weight-based dosing among African-American participants with genotype 1 infection. Twice as many of these patients cleared the virus when treated with the weight-based RBV regimen vs. the flat dose (21% vs. 10%); a lower rate was shown in the general study population with genotype 1 HCV, 34% vs. 28.9%. (However, the fact that over 300 patients with an end of treatment response missed their 24-week, post-treatment follow-up appointment accounts for some treatment failures under a strict intent-to-treat analysis.)

"These results are particularly significant for African-Americans, a group with known lower rates of response to HCV therapy than reported in other ethnic groups. Weight-based dosing vs. flat dosing clearly showed the greatest therapeutic impact in this group," says Dr. Jacobson.

"The study data strongly suggest adopting a 1400 mg/dose for patients who weigh more than 105 kg. In my opinion, the larger dose provides an opportunity for very heavy patients to have the same chance of cure as lighter patients without compromising safety," says Dr. Jacobson.

Overall safety with weight-based dosing was similar to that of the flat 800 mg dose. There was no difference in the occurrence of serious adverse events in the entire group, as well as in the African-American group.

Researchers at NewYork-Presbyterian/Weill Cornell are at the forefront of developing more effective prescription therapy for patients with HCV genotype 1 and are testing many drugs in various stages of development.

Collaborating with the study's principal investigator Dr. Jacobson was Dr. Robert S. Brown Jr., co-principal investigator of the study and associate professor of clinical medicine at Columbia University College of Physicians and Surgeons; and chief of clinical hepatology and medical director of the
'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
2. Work time is the largest influence to the duration of a persons sleep
3. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
4. Texas Largest Physician Carrier Announces 5th Successive Rate Cut on Anniversary of Lawsuit Reform
5. A Place for Mom, Nations Largest Senior Care Referral Service, Fills a Gap in Employee Benefits
6. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
7. Worlds Largest Exhibit of Princess Dianas Dresses Hosted by Appleton Museum
8. Largest Privately-Owned Veterinary Practice in the World, Banfield, the Pet Hospital(R), Appoints New Chief Executive Officer
9. Plenary lectures announced for worlds largest osteoporosis congress
10. The Integrated Benefits Institute Offers Largest Benchmarking Database in U.S. Spanning Disability and Workers Compensation Programs
11. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... News) -- Complications are rare among breast cancer ... study indicates. However, the researchers did find ... slightly higher risk for certain complications than a ... 18,000 breast cancer patients who had a single ... reconstruction and were followed for 30 days after ...
(Date:9/2/2014)... 2, 2014 In a large population-based study ... that mild cognitive impairment (MCI) occurred twice more ... 2. Interestingly, this strong association was only observed ... participants (66-80 years) the association vanished. This study ... Disease . , The concept of MCI describes ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Medex ... location of their corporate headquarters in Coral Springs, Fla. ... have exceeded our business development objectives for the 2014 ... Neil Herbst. “Our industry has requested a higher level ... utilization reviews. Medex has delivered, and the industry has ...
(Date:9/2/2014)... Kathleen Doheny HealthDay ... The U.S. obesity epidemic is a driving force behind the ... study. Researchers looked at data from five national surveys ... increase in diabetes over time could be explained by factors ... U.S. adults. The investigators found that the prevalence of ...
(Date:9/2/2014)... -- Melatonin supplements did not reduce delirium in seniors ... found. Many older hospital patients experience the sudden, ... their normal sleep-wake cycle. A lack of the hormone ... but there has been little research into whether melatonin ... 378 patients, average age 84, who had hip fracture ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3
... Minn. -- A Mayo Clinic study of a drug that ... demonstrates that the drug may also be effective in treating ... The study, which was done in mouse models, is featured ... , The National Cancer Institute reports that of 240,510 ...
... physicians not to disclose bad news to ill loved ... be truthful to the patient with the familys belief ... more successfully manage these conflicts, researchers at the University ... at Stanford University, have developed an approach based on ...
... is overweight when she becomes pregnant, the probability is ... when he/she reaches school age, according to a new ... Alina Rodriguez at Uppsala University in collaboration with international ... of Obesity. , The study, comprising more than 12,500 ...
... Global Med Technologies(R),Inc. (OTC Bulletin Board: GLOB), ... presenting at the Acumen Biofin,Rodman & Renshaw 9th ... the New York Palace Hotel in New York ... Tuesday, November 6th, at 11:15 a.m. EST, Dr. ...
... Technologies,Corporation (Nasdaq: DVAX ) announced today Michael S. ... overview of the,company at two investor conferences in New ... at the CIBC World Markets 18th Annual,Healthcare Conference on ... PT). In addition, Ostrach will present at the Acumen ...
... Arete Therapeutics Inc. today,announced the initiation of ... compound,AR9281, for the treatment of hypertension. AR9281 is ... a novel target,for the treatment of hypertension. The ... and will evaluate the safety, tolerability,pharmacokinetics and pharmacodynamics ...
Cached Medicine News:Health News:Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer 2Health News:Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer 3Health News:Don't tell mother she has cancer 2Health News:Overweight mothers run greater risk of having hyperactive children 2Health News:Global Med Technologies(R) to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3
(Date:9/2/2014)... , Sept. 2, 2014 Reportbuyer.com ... Global Markets and Technologies for Molecular Imaging ... STUDY GOALS AND OBJECTIVES The objectives of ... at molecular imaging devices used for diagnostic purposes, ... market and all possible market segments as well ...
(Date:9/2/2014)... 2, 2014 Reportbuyer.com has added a ... Global Markets for Services and Devices ... Bariatric surgery or weight loss surgery is a ... processes that deal with the surgical treatment of ... (endoluminal) and performed in both open and laparoscopic ...
(Date:9/2/2014)... , Sept. 2, 2014 Astellas has appointed ... intellectual property (IP) in the Americas. Kellerman will report ... & general counsel at Astellas. In his new role, ... partner with the business and manage the region,s intellectual ... "I am very pleased to welcome Jim ...
Breaking Medicine Technology:Global Markets and Technologies for Molecular Imaging Devices 2Global Markets and Technologies for Molecular Imaging Devices 3Global Markets and Technologies for Molecular Imaging Devices 4Global Markets and Technologies for Molecular Imaging Devices 5Global Markets and Technologies for Molecular Imaging Devices 6Global Markets and Technologies for Molecular Imaging Devices 7Global Markets and Technologies for Molecular Imaging Devices 8Global Markets and Technologies for Molecular Imaging Devices 9Global Markets and Technologies for Molecular Imaging Devices 10Global Markets and Technologies for Molecular Imaging Devices 11Global Markets and Technologies for Molecular Imaging Devices 12Global Markets and Technologies for Molecular Imaging Devices 13Global Markets and Technologies for Molecular Imaging Devices 14Global Markets and Technologies for Molecular Imaging Devices 15Global Markets and Technologies for Molecular Imaging Devices 16Global Markets and Technologies for Molecular Imaging Devices 17Global Markets and Technologies for Molecular Imaging Devices 18Global Markets and Technologies for Molecular Imaging Devices 19Global Markets and Technologies for Molecular Imaging Devices 20Global Markets and Technologies for Molecular Imaging Devices 21Global Markets and Technologies for Molecular Imaging Devices 22Global Markets and Technologies for Molecular Imaging Devices 23Global Markets and Technologies for Molecular Imaging Devices 24Global Markets and Technologies for Molecular Imaging Devices 25Bariatric Surgery: Global Markets for Services and Devices 2Bariatric Surgery: Global Markets for Services and Devices 3Bariatric Surgery: Global Markets for Services and Devices 4Bariatric Surgery: Global Markets for Services and Devices 5Bariatric Surgery: Global Markets for Services and Devices 6Bariatric Surgery: Global Markets for Services and Devices 7Bariatric Surgery: Global Markets for Services and Devices 8Bariatric Surgery: Global Markets for Services and Devices 9Bariatric Surgery: Global Markets for Services and Devices 10Bariatric Surgery: Global Markets for Services and Devices 11Bariatric Surgery: Global Markets for Services and Devices 12
... NATICK, Mass. and BARCELONA, Spain, May 20 Boston ... results from an analysis of economic and quality of ... SYNTAX trial. The results found that percutaneous coronary ... System was consistently associated with fewer patient hospital days ...
... suggest pirfenidone may provide meaningful clinical benefit in IPF ... safety reported -- Conference Call and Webcast at 9 ... 19 InterMune, Inc. (Nasdaq: ITMN ) ... studies evaluating pirfenidone in patients with idiopathic pulmonary fibrosis ...
Cached Medicine Technology:SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12
... Spinal Implant system. Material that has a ... bone. The result is an implant that ... support, while optimizing the fusion environment through ... anatomic design with 5 and 10 degrees ...
Cervical distraction screw retractor blade with Casper style distractor...
... Panther Retractor is two system in ... use for all cervicle spine retraction ... aluminium facilitate soft tissue retraction and ... intra-operative imaging with minimal interference. Two ...
Cloward cervical retractor. Size 18 mm....
Medicine Products: